Jiudian Pharmaceutical announced that the company plans to terminate the “New Antimicrobial Peptide Drug Research and Development Project” and permanently supplement the remaining capital raised by the project with 98.4918 million yuan in working capital for daily operating activities related to the main business. The current reflow amount accounts for 36.48% of the total amount of convertible bonds raised in 2021. As of June 30, 2026, the project has invested a total of 3.015,600 yuan in capital raised, with an investment progress of 3.07%. The matter has been reviewed and approved by the board of directors of the company and still needs to be submitted to the shareholders' meeting for consideration.

Jiudian Pharmaceutical announced that the company plans to terminate the “New Antimicrobial Peptide Drug Research and Development Project” and permanently supplement the remaining capital raised by the project with 98.4918 million yuan in working capital for daily operating activities related to the main business. The current reflow amount accounts for 36.48% of the total amount of convertible bonds raised in 2021. As of June 30, 2026, the project has invested a total of 3.015,600 yuan in capital raised, with an investment progress of 3.07%. The matter has been reviewed and approved by the board of directors of the company and still needs to be submitted to the shareholders' meeting for consideration.